ReviewNature reviews. Rheumatology2012
Developments in therapies for spondyloarthritis.
Review in Nature reviews. Rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis.Scientific reports · 2016Pooled it
- Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Annals of the rheumatic diseases · 2014Pooled it
- Tomography-guided palisade sacroiliac joint radiofrequency neurotomy versus celecoxib for ankylosing spondylitis: a open-label, randomized, and controlled trial.Rheumatology international · 2014Trial
- Risk of malignancies in patients with spondyloarthritis treated with biologics compared with those treated with non-biologics: a systematic review and meta-analysis.Therapeutic advances in musculoskeletal disease · 2020Article
- Features of trunk muscle weakness in patients with ankylosing spondylitis: A cross-sectional study.Biomedical journal · 2019Article
- Targeted Delivery of the HLA-BMediators of inflammation · 2017Article
- New evidence on the management of spondyloarthritis.Nature reviews. Rheumatology · 2016Review
- Rare Bone Marrow Biopsy Complication: A Challenging Case of Sacroiliitis and Staphilococcus Aureus Sepsis.Clinics and practice · 2016Article
- Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations.Drugs & aging · 2015Review
- Regulation of tumour necrosis factor signalling: live or let die.Nature reviews. Immunology · 2015Review
- Effect of cigarette smoking and alcohol consumption on disease activity and physical functioning in ankylosing spondylitis: a cross-sectional study.International journal of clinical and experimental medicine · 2015Article
- Article
- HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats.PloS one · 2015Article
- Biological therapies for spondyloarthritis.Therapeutic advances in musculoskeletal disease · 2014Review
- Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond.Arthritis & rheumatology (Hoboken, N.J.) · 2014Review
- Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.Mediators of inflammation · 2014Article
- Adalimumab and Non-Arteritic Anterior Ischaemic Optic Neuropathy: A Case Report.Neuro-ophthalmology (Aeolus Press) · 2014Article
- 17 and 23: prime numbers for ankylosing spondylitis?Lancet (London, England) · 2013Article
- Bone research in 2012: the ups and downs of bone in health and rheumatic disease.Nature reviews. Rheumatology · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
First-line therapy for spondyloarthritis (SpA) has not yet altered in the wake of new classification criteria; NSAIDs and physical therapy are recommended. Anti-TNF agents can be used when NSAIDs fail, but their efficacy has potentially been limited in previous trials by inclusion criteria requiring the presence of established, active disease. Now, not only patients with axial SpA (axSpA) with radiographic signs of sacroiliitis (that is, with ankylosing spondylitis), but also patients in whom structural damage is not-yet-visible radiographically (non-radiographic axSpA) can be included in trials of therapy for axSpA. TNF blockers, it seems already, are at least similarly effective in patients with non-radiographic axSpA as in those with established AS. Short symptom duration and a positive C-reactive protein test at baseline are currently the best predictors for a good response to TNF-blocking agents. Biologic agents besides anti-TNF therapies have so far failed in the treatment of axSpA. New bone formation seems currently to be best prevented by NSAIDs, not by TNF blockers. Whether earlier effective treatment of bony inflammation with anti-TNF therapy will be able to prevent ossification at a later stage has yet to be determined. New classification criteria for peripheral SpA will also allow treatment trials to be conducted more systematically than has previously been possible in this subgroup of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.